The US Food and Drug Administration (FDA) has granted orphan drug designation to a treatment for methylmalonic acidaemia (MMA). GENE202, developed by biotechnology company Genespire, is an in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to treat paediatric patients affected by genetic diseases. GENE02, which has also been granted orphan drug designation by the European Commission […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!